Abbott Laboratories (ABT.SW) shares dropped 13.50% pre-market to CHF86.50 on the SIX exchange, testing near-term support at CHF85.00 due to weak session flow and sector rotation. Despite oversold technical signals and a “BUY” rating from Meyka AI with significant upside potential, mixed analyst sentiment and upcoming earnings on April 15, 2026, present caution for investors. The article details technicals, valuation, risks, and analyst targets, suggesting a risk-adjusted target range of CHF95.00–CHF110.00.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
ABT.SW Abbott Laboratories (SIX) down 13.50% pre-market: CHF86.50 support to watch
Abbott Laboratories (ABT.SW) shares dropped 13.50% pre-market to CHF86.50 on the SIX exchange, testing near-term support at CHF85.00 due to weak session flow and sector rotation. Despite oversold technical signals and a “BUY” rating from Meyka AI with significant upside potential, mixed analyst sentiment and upcoming earnings on April 15, 2026, present caution for investors. The article details technicals, valuation, risks, and analyst targets, suggesting a risk-adjusted target range of CHF95.00–CHF110.00.